BICD1

Across TCGA pan-cancer cohorts, BICD1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BICD1 data layer compared with 23 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BICD1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BICD1 expression acts as an unfavorable survival marker.

CCRCC, HNSC, and LUAD are the cancer types where BICD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.888	1.000	.003	44	view →
HNSC	DFS	Median	III,IV	0.919	1.000	.023	10	view →
LUAD	OS	Median	All	0.920	0.999	.012	10	view →
PDAC	OS	Quartile	II,III,IV	0.302	0.534	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BICD1–CCRCC (OS)

Open the CCRCC breakdown →